CD8A and neoplasm: Compared to the anti‐PD‐L1, M7824 maintains the antibody‐mediated anti‐tumour capacity, increases expression of molecules contributed to the trafficking of T cells within tumour area, boosts tumour lytic activity of antigen‐specific CD8+ T cells and enhances tumour cell lytic activity of TRAIL.92